We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned a consensus rating of “Moderate Buy” from ...

Acadia Pharmaceuticals ACAD reported fourth-quarter 2024 earnings of 17 cents per share, missing the Zacks Consensus Estimate of 19 cents.The reported figure has been adjusted for the net proceeds ...

Charles Schwab Investment Management Inc. lessened its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.28 per share a year ago.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

SAN DIEGO & COPENHAGEN, Denmark, March 03, 2025--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) and Saniona (OMX: SANION) today announced the successful completion of the two ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the fourth quarter and full year ended December 31, 2024. “We closed 2024 on a ...